Recordati Industria Chimica e Farmaceutica

RECORDATI: PUBLICATION OF DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 29.04.2025

Milan, 24th March 2025 - Please be informed that the following reports approved by the Board of Directors of Recordati S.p.A. on 18 th March 2025:

(i) the Report on the 2025 Remuneration policy and the remuneration paid for 2024;
(ii) the Directors' Reports relating to the following items of the agenda of the Ordinary Shareholders' Meeting called for the 29th April 2025:
- item no. 3 (Report on the Remuneration policy and the remuneration paid) which includes, as its annex, the Report on Remuneration policy and the remuneration paid referred to in point (i); and
- item no. 4 (Authorization to the purchase and disposal of treasury stock),

are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.it, the first report in the Governance - Remuneration section; and the other reports in the Investors - Shareholder Information section) and on the '' storage mechanism ().

Recordati is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of "unlocking the full potential of life" aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.

Investor Relations

Eugenia Litz +44 7824 394 750 [email protected] Gianluca Saletta +39 348 979 4876 [email protected]

Media Relations

ICR Healthcare US: Alexis Feinberg +1 203 939 2225 [email protected]

UK, Europe & Rest of World: Jessica Hodgson +44 7561 424 788 [email protected]